New information about the polymyxin/colistin class of antibiotics

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 17, 2009, Pages 2811-2828

  Molina, José ^a   Cordero, Elisa ^a   Pachón, Jerónimo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Acinetobacter baumannii; Colistimethate; Colistin; Heteroresistance; Klebsiella pneumoniae; Multi drug resistance; Panresistance; Polymyxin b; Polymyxins; Pseudomonas aeruginosa; Synergism; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; COTRIMOXAZOLE; DEXAMETHASONE; HYDROCORTISONE; IMIPENEM; MEROPENEM; MOXIFLOXACIN; NEOMYCIN; POLYMYXIN; POLYMYXIN B; RIFAMPICIN; SULTAMICILLIN; TOBRAMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ATAXIA; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; BRAIN VENTRICULITIS; BRONCHOSPASM; CATHETER INFECTION; CHEST TIGHTNESS; CLINICAL TRIAL; CONJUNCTIVITIS; COUGHING; DRUG FEVER; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENDOCARDITIS; EXTERNAL OTITIS; HUMAN; HYPOACUSIS; IN VITRO STUDY; INFECTIOUS ARTHRITIS; KLEBSIELLA PNEUMONIAE INFECTION; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OSTEOMYELITIS; OTITIS MEDIA; PARESTHESIA; PNEUMONIA; POLYNEUROPATHY; PRURITUS; PSEUDOMONAS INFECTION; RASH; REVIEW; SEPSIS; SOFT TISSUE INFECTION; SORE THROAT; SURGICAL INFECTION; TRACHEOBRONCHITIS; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VISUAL DISORDER;

ANTI-BACTERIAL AGENTS; COLISTIN; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; POLYMYXINS;

EID: 73149085302     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903334185     Document Type: Review

References (112)

1. Benedict RG, Langlykke AF. Antibiotic activity of bacillus polymyxa. J Bacteriol 1947;54:24-25
2. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-1341
3. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27
4. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev 2008;21:449-465
5. Kaye KM, Kaye D. Polymyxins (polymyxin B and colistin). In: Mandell GL, Bennett JE, Dolin R, editors, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 6th edition. Philadelphia: Churchill Livingstone; 2005. p. 435-436
6. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007;11:R47
7. European Antimicrobial Resistance Surveillance System (EARSS), 2008. Available from: http://www.rivm.nl/earss [Last accessed 11 July 2009]
8. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant gram-negative bacilli in Europe. Euro Surveill 2008;13(47):1-11
9. Valencia R, Arroyo LA, Conde M, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 2009;30:257-263
10. Landman D, Bratu S, Alam M, Quale J. Citywide emergence of pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 2005;55:954-957
11. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001 - 2004). Clin Microbiol Infect 2006;12:315-321
12. CastanheiraM, Sader HS, Deshpande LM, et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008;52:570-573
13. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth Informational Suplemment. Document M100-S19. Wayne, Pa, CA, USA; 2009
14. Clinical breakpoints. European Committee on Antimicrobial Susceptibility Testing (EUCAST), 2008. Available from: http://www.srga.org/ eucastwt/MICTAB/index.html. [Last accessed 16 July 2009]
15. Matthaiou DK, Michalopoulos A, Rafailidis PI, et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008;36:807-811
16. Bergen PJ, Li J, Nation RL, et al. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 2008;61:636-642
17. Souli M, Rekatsina PD, Chryssouli Z, et al. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing klebsiella pneumoniae isolates? Antimicrob Agents Chemother 2009;53:2133-2135
18. Elemam A, Rahimian J, Mandell W. Infection with panresistant klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009;49:271-274
19. Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug-resistant acinetobacter baumannii. Antimicrob Agents Chemother 2006;50:2946-50
20. In vitro pharmacodynamics of colistin against multidrug-resistant klebsiella pneumoniae. J Antimicrob Chemother 2008;62:1311-1318
21. Yau W, Owen RJ, Poudyal A, et al. Colistin hetero-resistance in multidrug-resistant acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 2009;58:138-144
22. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008;52:351-352
23. Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005;25:11-25
24. Song JY, Kee SY, Hwang IS, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant acinetobacter baumannii. J Antimicrob Chemother 2007;60:317-322
25. Yoon J, Urban C, Terzian C, et al. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant acinetobacter baumannii. Antimicrob Agents Chemother 2004;48:753-757
26. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant acinetobacter baumannii. Diagn Microbiol Infect Dis 2001;40:117-120
27. Wareham DW, Bean DC. In vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob 2006;5:10. doi:10.1186/1476-0711-5-10 (Pubitemid 43983307)
28. Timurkaynak F, Can F, Azap OK, et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of pseudomonas aeruginosa and acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006;27:224-228
29. Pankey GA, Ashcraft DS. The detection of synergy between meropenem and polymyxin B against meropenem-resistant acinetobacter baumannii using Etest and time-kill assay. Diagn Microbiol Infect Dis 2009;63:228-232
30. Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against pseudomonas aeruginosa and acinetobacter baumannii. Antimicrob Agents Chemother 2008;52:333-336
31. Tan TY, Ng LS, Tan E, Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007;60:421-423
32. Aoki N, Tateda K, Kikuchi Y, et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant pseudomonas aeruginosa. J Antimicrob Chemother 2009;63:534-542
33. Montero A, Ariza J, Corbella X, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004;54:1085-1091
34. Cirioni O, Ghiselli R, Orlando F, et al. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant pseudomonas aeruginosa strain. Crit Care Med 2007;35:1717-1723
35. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008;14:816-827
36. Falagas ME, Kasiakou SK. Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother 2006;50:2274-2275
37. Li J, Nation RL, Turnidge JD. Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization. Antimicrob Agents Chemother 2006;50:4231-4232
38. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with gram-negative bacterial infections. Antimicrob Agents Chemother 2009; published online 11 May 2009, doi:10.1128/AAC.01361-08
39. Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001;27:355-362
40. Kwon KT, Oh WS, Song JH, et al. Impact of imipenem resistance on mortality in patients with acinetobacter bacteraemia. J Antimicrob Chemother 2007;59:525-530
41. Skiada A, Pavleas J, Vafiadi C, et al. O25 - Serum bactericidal activity of three different dosing regimens of colistin against pseudomonas aeruginosa. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Helsinki, Finland; 2009
42. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007;59:473-477
43. Li J, Rayner CR, Nation RL, et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005;49:4814-4815
44. Karvanen M, Plachouras D, Friberg LE, et al. P1660 - Pharmacokinetics of colistin after intravenous administration in critically ill patients receiving continuous venovenous haemodiafiltration. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Helsinki, Finland; 2009
45. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005;41:1159-1166
46. Amsden G. Tables of antimicrobial agent pharmacology. In: Mandell GL, Bennett JE, Dolin R, editors, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 6th edition. Philadelphia: Churchill Livingstone; 2005. p. 668-669
47. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-1118
48. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007;33:1162-1167
49. Falagas ME, Kasiakou SK, Kofteridis DP, et al. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006;25:596-599
50. Furtado GH, d'Azevedo PA, Santos AF, et al. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant pseudomonas aeruginosa. Int J Antimicrob Agents 2007;30:315-319
51. Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant pseudomonas aeruginosa. Clin Infect Dis 2003;37:e154-60
52. Michalopoulos AS, Tsiodras S, Rellos K, et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115-121
53. Pintado V, San Miguel LG, Grill F, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008;56:185-190
54. Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002;46:1946-1952
55. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria: a prospective study. Respir Med 2008;102:407-412
56. Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and pseudomonas infections: a prospective cohort study. Intensive Care Med 2005;31:1058-1065
57. Michalopoulos A, Kasiakou SK, Mastora Z, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-9
58. Falagas ME, Siempos, Rafailidis PI, et al. Inhaled colistin as monotherapy for multidrug-resistant gram nosocomial pneumonia: a case series. Respir Med 2009;103:707-713
59. Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant acinetobacter baumannii and pseudomonas aeruginosa. Clin Infect Dis 2005;41:754-757
60. Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007;58:235-240
61. Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant pseudomonas aeruginosa. Clin Infect Dis 2003;37:e154-60
62. Falagas ME, Rafailidis PI, Kasiakou SK, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 2006;12:1227-1230
63. Petrosillo N, Chinello P, Proietti MF, et al. Combined colistin and rifampicin therapy for carbapenem-resistant acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005;11:682-683
64. Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant acinetobacter baumannii infections. J Antimicrob Chemother 2008;61:417-420
65. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant acinetobacter baumannii. J Infect 2006;53:274-278
66. Kollef MH. An empirical approach to the treatment of multidrug-resistant ventilator-associated pneumonia. Clin Infect Dis 2003;36:1119-1121
67. Rios FG, Luna CM, Maskin B, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 2007;30:307-313
68. Guidelines for the management of adults with hospital-acquired, ventilator-associated, healthcare-associated pneumonia. Am J Respir Crit. Care Med 2005;171:388-416
69. Knowless M, Gilligan PH, Boucher RC. Cystic fibrosis. In: Mandell GL, Bennett JE, Dolin R, editors, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 6th edition. Philadelphia: Churchill Livingstone; 2005. p. 870-874
70. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-335
71. Antibiotic treatment for cystic fibrosis. Consensus document. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group,2009. Available from: http://www. cftrust.org.uk/aboutcf/publications/ consensusdoc/. [Last accessed 20 June 2009]
72. Valerius NH, Koch C, Hoiby N. Prevention of chronic pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-726
73. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008;7:523-530
74. Doring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3:67-91
75. Wood DM, Smyth AR. Antibiotic strategies for eradicating pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2006;CD004197
76. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003;CD001021
77. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-664
78. Adeboyeku D, Scott S, Hodson ME. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J Cyst Fibros 2006;5:261-263
79. Steinfort DP, Steinfort C. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 2007;37:495-498
80. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2005;CD002007
81. Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant acinetobacter species. Lancet Infect Dis 2009;9:245-255
82. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 2007;29:9-25
83. Fernandez-Viladrich P, Corbella X, Corral L, et al. Successful treatment of ventriculitis due to carbapenem-resistant acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 1999;28:916-917
84. Jimenez-Mejias ME, Becerril B, Marquez-Rivas FJ, et al. Successful treatment of multidrug-resistant acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Eur J Clin Microbiol Infect Dis 2000;19:970-971
85. Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, et al. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002;21:212-214
86. Ng J, Gosbell IB, Kelly JA, et al. Cure of multiresistant acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 2006;58:1078-1081
87. Rodriguez GA, Blanco A, Asensi V, et al. Multidrug-resistant acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother 2008;61:908-913
88. Kasiakou SK, Michalopoulos A, Soteriades ES, et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005;49:3136-3146
89. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-1011
90. Jin L, Li J, Nation RL, Nicolazzo JA. Brain penetration of colistin in mice assessed by a novel high-performance liquid chromatographic technique. Antimicrob Agents Chemother 2009; published online 10 August 2009, doi:10.1128/AAC.00485-09
91. Segal-Maurer S, Mariano N, Qavi A, et al. Successful treatment of ceftazidime-resistant klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis 1999;28:1134-1138
92. Hayes E, Yow E. Meningitis due to pseudomonas aeruginosa treated with polymyxin B. Am J Med Sci 1950;220:633-637
93. Montero M, Horcajada JP, Sorli L, et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant pseudomonas aeruginosa infections. Infection 2009; published online 4 June 2009, doi 10.1007/s15010-009-8342-x
94. Rodriguez-Hernandez MJ, Jimenez-Mejias ME, Pichardo C, et al. Colistin efficacy in an experimental model of acinetobacter baumannii endocarditis. Clin Microbiol Infect 2004;10:581-584
95. Benenson S, Navon-Venezia S, Carmeli Y, et al. Carbapenem-resistant klebsiella pneumoniae endocarditis in a young adult. Successful treatment with gentamicin and colistin. Int J Infect Dis 2009; published online 28 March 2009, doi:10.1016/j.ijid.2009.01.006
96. Yoshikawa TT, Bayer AS, Guze LB. Endocarditis due to pseudomonas aeruginosa in a heroin addict. Successful treatment with trimethoprim- sulfamethoxazole mixture plus colistin. Chest 1977;72:794-796
97. Tascini C, Gemignani G, Palumbo F, et al. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother 2006;18:648-651 (Pubitemid 46045396)
98. Dohar JE, Roland P, Wall GM, et al. Differences in bacteriologic treatment failures in acute otitis externa between ciprofloxacin/dexamethasone and neomycin/polymyxin B/hydrocortisone: results of a combined analysis. Curr Med Res Opin 2009;25:287-291
99. Drehobl M, Guerrero JL, Lacarte PR, et al. Comparison of efficacy and safety of ciprofloxacin otic solution 0.2% versus polymyxin B-neomycin- hydrocortisone in the treatment of acute diffuse otitis externa. Curr Med Res Opin 2008;24:3531-3542
100. Miro N. Controlled multicenter study on chronic suppurative otitis media treated with topical applications of ciprofloxacin 0.2% solution in single-dose containers or combination of polymyxin B, neomycin, and hydrocortisone suspension. Otolaryngol Head Neck Surg 2000;123:617-623
101. Schwartz RH. Once-daily ofloxacin otic solution versus neomycin sulfate/ polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa. Curr Med Res Opin 2006;22:1725-1736
102. Cantrell HF, Lombardy EE, Duncanson FP, et al. Declining susceptibility to neomycin and polymyxin B of pathogens recovered in otitis externa clinical trials. South Med J 2004;97:465-471
103. Granet DB, Dorfman M, Stroman D, Cockrum P. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus 2008;45:340-349
104. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445-2452
105. Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005;5:1. doi:10.1186/1471-2334-5-1 (Pubitemid 41363780)
106. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008;56:432-436
107. Oliveira MS, Prado GV, Costa SF, et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant acinetobacter spp. J Antimicrob Chemother 2008;61:1369-1375
108. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-2662
109. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003;7:R78-83
110. Cunningham S, Prasad A, Collyer L, et al. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 2001;84:432-433
111. Alothman GA, Ho B, Alsaadi MM, et al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005;127:522-529
112. Rodriguez-Bano J, Garcia L, Ramirez E, et al. Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive 'bundle' approach. Am J Infect Control 2009; published online 19 May 2009, doi:10.1016/j.ajic.2009.01.008